Tianjin Ringpu Bio Tech Total Assets
Tianjin Ringpu Bio Tech total assets. Based on the latest financial reports, Tianjin Ringpu Bio Tech (300119) holds total assets worth CN¥7.80 Billion CNY (≈ $1.14 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 300119 stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Tianjin Ringpu Bio Tech (2007–2025)
Total assets of Tianjin Ringpu Bio Tech from 2007 to 2025. This chart illustrates how Tianjin Ringpu Bio Tech's total assets have evolved over time, based on quarterly financial data. See 300119 share price today for real-time trading data and today's change.
Tianjin Ringpu Bio Tech - Asset Composition Analysis
Tianjin Ringpu Bio Tech Total Assets Breakdown (December 2025)
Tianjin Ringpu Bio Tech total assets breakdown as of December 2025. Tianjin Ringpu Bio Tech's total assets of CN¥7.80 Billion consist of 44.1% current assets and 55.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.5% |
| Accounts Receivable | CN¥983.60 Million | 12.9% |
| Inventory | CN¥502.12 Million | 6.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥681.10 Million | 8.9% |
| Goodwill | CN¥442.99 Million | 5.8% |
Asset Composition Trend (2007–2025)
This chart illustrates how Tianjin Ringpu Bio Tech's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Tianjin Ringpu Bio Tech short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tianjin Ringpu Bio Tech's current assets represent 44.1% of total assets in 2025, a decrease from 62.5% in 2007.
- Cash Position: Cash and equivalents constituted 8.5% of total assets in 2025, down from 25.5% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 7.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 12.9% of total assets.
Tianjin Ringpu Bio Tech Competitors by Total Assets
Key competitors of Tianjin Ringpu Bio Tech based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.86 Billion |
|
H Lundbeck A/S
CO:HLUN-B
|
Denmark | Dkr54.01 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Viyash Scientific Limited
NSE:SEQUENT
|
India | Rs17.26 Billion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥5.11 Billion |
Tianjin Ringpu Bio Tech - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.81 | 1.74 | 1.67 |
| Quick Ratio | 1.54 | 1.50 | 1.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.58 Billion | CN¥1.59 Billion | CN¥697.63 Million |
Tianjin Ringpu Bio Tech - Advanced Valuation Insights
This section examines the relationship between Tianjin Ringpu Bio Tech's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.73 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | -3.9% |
| Total Assets | CN¥7.66 Billion |
| Market Capitalization | $1.15 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Tianjin Ringpu Bio Tech's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Tianjin Ringpu Bio Tech's assets decreased by 3.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Tianjin Ringpu Bio Tech (2007–2025)
The table below shows the annual total assets of Tianjin Ringpu Bio Tech from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥7.66 Billion ≈ $1.12 Billion |
-3.89% |
| 2024-12-31 | CN¥7.97 Billion ≈ $1.17 Billion |
+20.77% |
| 2023-12-31 | CN¥6.60 Billion ≈ $965.19 Million |
+8.02% |
| 2022-12-31 | CN¥6.11 Billion ≈ $893.54 Million |
+7.30% |
| 2021-12-31 | CN¥5.69 Billion ≈ $832.74 Million |
+45.95% |
| 2020-12-31 | CN¥3.90 Billion ≈ $570.58 Million |
+9.43% |
| 2019-12-31 | CN¥3.56 Billion ≈ $521.42 Million |
+18.84% |
| 2018-12-31 | CN¥3.00 Billion ≈ $438.77 Million |
+2.54% |
| 2017-12-31 | CN¥2.92 Billion ≈ $427.90 Million |
+6.99% |
| 2016-12-31 | CN¥2.73 Billion ≈ $399.95 Million |
+16.37% |
| 2015-12-31 | CN¥2.35 Billion ≈ $343.67 Million |
+18.44% |
| 2014-12-31 | CN¥1.98 Billion ≈ $290.17 Million |
-1.01% |
| 2013-12-31 | CN¥2.00 Billion ≈ $293.12 Million |
+11.70% |
| 2012-12-31 | CN¥1.79 Billion ≈ $262.42 Million |
+7.31% |
| 2011-12-31 | CN¥1.67 Billion ≈ $244.55 Million |
+3.01% |
| 2010-12-31 | CN¥1.62 Billion ≈ $237.41 Million |
+290.84% |
| 2009-12-31 | CN¥415.11 Million ≈ $60.74 Million |
+23.86% |
| 2008-12-31 | CN¥335.15 Million ≈ $49.04 Million |
+79.74% |
| 2007-12-31 | CN¥186.46 Million ≈ $27.29 Million |
-- |
About Tianjin Ringpu Bio Tech
Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sale of veterinary raw materials, pharmaceutical preparation, functional additives, and veterinary biological products. The company provides vaccines, chemical drugs, traditional Chinese medicines; feed additives, including pigs, chickens, waterfowl, cattle, sheep and pet medicines, and vaccines; and p… Read more